ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101

Its studies are mostly in Ovarian Neoplasms, led by Outpace Bio.

Furthest: phase 1, since Jun 12, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Outpace Bio10 open or runningphase 1since Jun 12, 2025Jun 12, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07030907 · 3 enrolled · United States

TargetBeta

“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and conditionally expressing the human cytokine interleukin-2 (IL-2) and containing an epidermal growth f”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030907Ovarian Neoplasms · United States1TerminatedSep 30, 20263

How it is read

Names in the registry

  • “OPB-101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.